LSTA
NASDAQ · Biotechnology
Lisata Therapeutics Inc
$5.02
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
1.08M
Net Income
-21,628,993
Gross Margin
9.6%
Profit Margin
-1,998.5%
Rev Growth
-59.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 9.6% | 9.6% | 60.2% | 60.2% |
| Operating Margin | -2,240.9% | -2,016.8% | -3.8% | -3.7% |
| Profit Margin | -1,998.5% | -1,898.6% | -3.8% | -3.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.08M | 2.65M | 5.21M | 4.72M |
| Gross Profit | 103.5K | 253.4K | 3.14M | 2.84M |
| Operating Income | -24,260,453 | -53,450,202 | -199,396 | -176,250 |
| Net Income | -21,628,993 | -47,652,616 | -195,079 | -179,711 |
| Gross Margin | 9.6% | 9.6% | 60.2% | 60.2% |
| Operating Margin | -2,240.9% | -2,016.8% | -3.8% | -3.7% |
| Profit Margin | -1,998.5% | -1,898.6% | -3.8% | -3.8% |
| Rev Growth | -59.2% | -59.2% | -0.3% | +24.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 21.25M | 18.39M |
| Total Equity | — | — | 13.67M | 13.06M |
| D/E Ratio | — | — | 1.55 | 1.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -24,342,308 | -56,610,018 | -244,954 | -200,080 |
| Free Cash Flow | — | — | -167,798 | -115,643 |